Patents by Inventor Arimichi Okazaki
Arimichi Okazaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200376111Abstract: A vaccine composition for administration to the oral cavity of a human or an animal, the vaccine composition containing at least one antigen derived from an infectious disease, and at least one selected from the group consisting of a toll-like receptor 4 (TLR4) agonist, a toll-like receptor 2/6 (TLR2/6) agonist, and cyclic dinucleotide, or a derivative or salt thereof.Type: ApplicationFiled: August 18, 2020Publication date: December 3, 2020Applicant: NITTO DENKO CORPORATIONInventors: Masahiro FUKASAKA, Arimichi OKAZAKI, Daisuke ASARI, Mitsuhiko HORI, Shizuo AKIRA, Osamu TAKEUCHI
-
Patent number: 10449144Abstract: The present invention provides a cancer vaccine composition for transdermal administration for inducing cellular immunity, comprising (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a cellular immunity induction promoter. The composition efficiently induces cellular immunity against a cancer in a subject.Type: GrantFiled: January 29, 2014Date of Patent: October 22, 2019Assignees: NITTO DENKO CORPORATION, OSAKA UNIVERSITYInventors: Katsuyuki Okubo, Yoshiki Maeda, Arimichi Okazaki, Daisuke Asari, Takuya Shishido, Mitsuhiko Hori, Haruo Sugiyama
-
Patent number: 10391167Abstract: The present disclosure relates to a method for inducing humoral immunity in a human or animal, that includes administering to the human or animal a mucosal vaccine composition to a mucous membrane selected from the group consisting of a human or animal intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, and rectal mucous membrane. The mucosal vaccine composition includes at least one antigen derived from a pathogen; and as an adjuvant, a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of Pantoea, Acetobacter, Zymomonas, and Xanthomonas, or a salt of the lipopolysaccharide, wherein the mass ratio between a total mass of the adjuvant and a total mass of the antigen is 0.002 to 500.Type: GrantFiled: October 2, 2014Date of Patent: August 27, 2019Assignee: NITTO DENKO CORPORATIONInventors: Masahiro Fukasaka, Mitsuhiko Hori, Katsuyuki Okubo, Daisuke Asari, Arimichi Okazaki, Eiji Kiyotoh, Kyohei Matsushita
-
Patent number: 10206985Abstract: The present invention provides a cancer vaccine composition for mucosal administration for inducing cellular immunity, comprising (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a cellular immunity induction promoter. The composition efficiently induces cellular immunity against a cancer in a subject.Type: GrantFiled: January 29, 2014Date of Patent: February 19, 2019Assignees: NITTO DENKO CORPORATION, OSAKA UNIVERSITYInventors: Daisuke Asari, Kyohei Matsushita, Arimichi Okazaki, Yoshiki Maeda, Katsuyuki Okubo, Mitsuhiko Hori, Haruo Sugiyama
-
Patent number: 10195258Abstract: The present invention provides a cancer vaccine tape preparation for inducing cellular immunity, comprising: a support, an adhesive layer comprising an adhesive disposed on one side of the support, wherein the adhesive layer carries a combination of: (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a first cellular immunity induction promoter. The tape preparation can provides high efficacy.Type: GrantFiled: January 29, 2014Date of Patent: February 5, 2019Assignees: NITTO DENKO CORPORATION, OSAKA UNIVERSITYInventors: Yoshiki Maeda, Katsuyuki Okubo, Daisuke Asari, Arimichi Okazaki, Takuya Shishido, Mitsuhiko Hori, Haruo Sugiyama
-
Patent number: 10092642Abstract: The present invention aims at providing a mucosal vaccine composition that can be administered to an intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, or rectal mucous membrane, that is useful as a prophylactic or therapeutic agent for infectious diseases or cancers, and is capable of safely and effectively inducing the systemic immune response and mucosal immune response.Type: GrantFiled: October 2, 2014Date of Patent: October 9, 2018Assignee: NITTO DENKO CORPORATIONInventors: Masahiro Fukasaka, Mitsuhiko Hori, Katsuyuki Okubo, Daisuke Asari, Arimichi Okazaki, Eiji Kiyotoh, Kyohei Matsushita
-
Patent number: 10076491Abstract: The invention provides a vaccine composition containing an antigen for inducing cellular immunity, comprising at least one first cellular immunity induction promoter.Type: GrantFiled: January 29, 2014Date of Patent: September 18, 2018Assignee: NITTO DENKO CORPORATIONInventors: Daisuke Asari, Katsuyuki Okubo, Takuya Shishido, Arimichi Okazaki, Yoshiki Maeda, Kyohei Matsushita, Wenjing Li, Mitsuhiko Hori, Haruo Sugiyama
-
Patent number: 10071155Abstract: The present invention provides a nasal mucosal vaccine composition which is safe, useful as a preventive or therapeutic agent for infectious diseases or cancers, and capable of inducing systemic immune responses and mucosal immune responses effectively.Type: GrantFiled: October 2, 2014Date of Patent: September 11, 2018Assignee: NITTO DENKO CORPORATIONInventors: Eiji Kiyotoh, Mitsuhiko Hori, Katsuyuki Okubo, Daisuke Asari, Arimichi Okazaki, Masahiro Fukasaka, Kyohei Matsushita
-
Patent number: 10071051Abstract: The present invention provides a cancer vaccine composition for transdermal administration for cellular immunity induction, comprising (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a pharmacologically acceptable acid as a first cellular immunity induction promoter, or a pharmacologically acceptable salt thereof.Type: GrantFiled: January 29, 2014Date of Patent: September 11, 2018Assignees: NITTO DENKO CORPORATION, OSAKA UNIVERSITYInventors: Katsuyuki Okubo, Yoshiki Maeda, Arimichi Okazaki, Daisuke Asari, Takuya Shishido, Mitsuhiko Hori, Haruo Sugiyama
-
Patent number: 9962439Abstract: The present invention aims at providing an injectable vaccine composition that is safe, useful as a prophylactic or therapeutic agent for cancers or infectious diseases, and capable of inducing the systemic immune response safely and effectively.Type: GrantFiled: October 2, 2014Date of Patent: May 8, 2018Assignee: NITTO DENKO CORPORATIONInventors: Kyohei Matsushita, Masahiro Fukasaka, Arimichi Okazaki, Eiji Kiyotoh, Katsuyuki Okubo, Daisuke Asari, Mitsuhiko Hori
-
Publication number: 20170246287Abstract: Disclosed is a vaccine composition for transdermal administration to induce cellular immunity, comprising an antigen, wherein Th1 cell ratio in a model animal for immunological evaluation that received the composition is 10% or more.Type: ApplicationFiled: October 28, 2016Publication date: August 31, 2017Applicant: NITTO DENKO CORPORATIONInventors: Takuya SHISHIDO, Katsuyuki OKUBO, Daisuke ASARI, Arimichi OKAZAKI, Yoshiki MAEDA, Kyohei MATSUSHITA, Wenjing LI, Mitsuhiko HORI, Haruo SUGIYAMA
-
Publication number: 20170224813Abstract: The present invention aims to provide a vaccine pharmaceutical composition that can be universally used for induction of cellular immunity to various antigens and that exerts a high inducing effect. The present invention relates to a vaccine pharmaceutical composition that suppresses apoptosis of CTL or inhibits suppression of induction of CTL.Type: ApplicationFiled: August 4, 2015Publication date: August 10, 2017Applicant: NITTO DENKO CORPORATIONInventors: Yoshiki MAEDA, Arimichi OKAZAKI, Daisuke ASARI, Mitsuhiko HORI
-
Patent number: 9707187Abstract: The problem of the present invention is to provide a composition for enhancing transdermal absorption of a drug, which shows a sufficiently high enhancing effect on transdermal absorption of a drug, particularly, a composition for enhancing transdermal absorption of a drug, which shows a sufficiently high enhancing effect on transdermal absorption of an acidic drug. A composition for enhancing transdermal absorption of a drug, comprising an unsaturated higher alcohol having 12-20 carbon atoms and a polyvalent alcohol having 3-8 carbon atoms. A composition for enhancing transdermal absorption of a drug, comprising an unsaturated higher alcohol having 12-20 carbon atoms, a polyvalent alcohol having 3-8 carbon atoms and an organic amine having 2-9 carbon atoms.Type: GrantFiled: September 12, 2012Date of Patent: July 18, 2017Assignee: NITTO DENKO CORPORATIONInventors: Arimichi Okazaki, Tsuyoshi Mukobata, Sachiko Sakamoto, Akinori Hanatani
-
Patent number: 9707189Abstract: The problem of the present invention is to provide a composition for enhancing transdermal absorption of a drug, which shows a sufficiently high enhancing effect on transdermal absorption of an acidic drug. A composition for enhancing transdermal absorption of an acidic drug, comprising a polyvalent alcohol having 3-8 carbon atoms, a higher alcohol having 12-20 carbon atoms and an organic amine having 2-9 carbon atoms.Type: GrantFiled: September 12, 2012Date of Patent: July 18, 2017Assignee: NITTO DENKO CORPORATIONInventors: Arimichi Okazaki, Tsuyoshi Mukobata, Sachiko Sakamoto, Akinori Hanatani
-
Publication number: 20170028054Abstract: An intraorally administrable vaccine composition useful to be a preventive or therapeutic agent for infectious diseases, and effectively induces a systemic immune response or a mucosal immune response is provided. A vaccine composition for administration to the oral cavity of a human or an animal, the vaccine composition containing at least one antigen derived from an infectious disease, and at least one selected from the group consisting of a toll-like receptor 4 (TLR4) agonist, a toll-like receptor 2/6 (TLR2/6) agonist, and cyclic dinucleotide, or a derivative or salt thereof.Type: ApplicationFiled: October 11, 2016Publication date: February 2, 2017Applicant: NITTO DENKO CORPORATIONInventors: Masahiro FUKASAKA, Arimichi OKAZAKI, Daisuke ASARI, Mitsuhiko HORI, Shizuo AKIRA, Osamu TAKEUCHI
-
Patent number: 9498527Abstract: An intraorally administrable vaccine composition useful to be a preventive or therapeutic agent for infectious diseases, and effectively induces a systemic immune response or a mucosal immune response is provided. A vaccine composition for administration to the oral cavity of a human or an animal, the vaccine composition containing at least one antigen derived from an infectious disease, and at least one selected from the group consisting of a toll-like receptor 4 (TLR4) agonist, a toll-like receptor 2/6 (TLR2/6) agonist, and cyclic dinucleotide, or a derivative or salt thereof.Type: GrantFiled: April 3, 2013Date of Patent: November 22, 2016Assignee: NITTO DENKO CORPORATIONInventors: Masahiro Fukasaka, Arimichi Okazaki, Daisuke Asari, Mitsuhiko Hori, Shizuo Akira, Osamu Takeuchi
-
Publication number: 20160287697Abstract: The present invention aims at providing an injectable vaccine composition that is safe, useful as a prophylactic or therapeutic agent for cancers or infectious diseases, and capable of inducing the systemic immune response safely and effectively.Type: ApplicationFiled: October 2, 2014Publication date: October 6, 2016Applicant: NITTO DENKO CORPORATIONInventors: Kyohei MATSUSHITA, Masahiro FUKASAKA, Arimichi OKAZAKI, Eiji KIYOTOH, Katsuyuki OKUBO, Daisuke ASARI, Mitsuhiko HORI
-
Publication number: 20160228540Abstract: The present invention provides a nasal mucosal vaccine composition which is safe, useful as a preventive or therapeutic agent for infectious diseases or cancers, and capable of inducing systemic immune responses and mucosal immune responses effectively.Type: ApplicationFiled: October 2, 2014Publication date: August 11, 2016Applicant: NITTO DENKO CORPORATIONInventors: Eiji KIYOTOH, Mitsuhiko HORI, Katsuyuki OKUBO, Daisuke ASARI, Arimichi OKAZAKI, Masahiro FUKASAKA, Kyohei MATSUSHITA
-
Publication number: 20160213773Abstract: The present invention aims at providing a vaccine composition capable of being administered to an intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, or rectal mucous membrane, that is safe, useful as a prophylactic or therapeutic agent for infectious diseases or cancers, and capable of effectively inducing the systemic immune response and mucosal immune response.Type: ApplicationFiled: October 2, 2014Publication date: July 28, 2016Applicant: NITTO DENKO CORPORATIONInventors: Masahiro FUKASAKA, Mitsuhiko HORI, Katsuyuki OKUBO, Daisuke ASARI, Arimichi OKAZAKI, Eiji KIYOTOH, Kyohei MATSUSHITA
-
Publication number: 20160206728Abstract: The present invention provides a dried influenza vaccine preparation in which the activity of an influenza vaccine antigen can be stably maintained even when stored without strictly maintaining a low temperature, and which can be stably supplied. The present invention also provides a method of producing the dried influenza vaccine preparation. The present invention provides a dried influenza vaccine preparation containing an influenza vaccine antigen and a disaccharide, wherein the disaccharide is at least one selected from the group consisting of sucrose, maltose, palatinose, melibiose, isomalt, cellobiose, allolactose, isomaltose, sophorose, lactobionic acid, laminaribiose, xylobiose, turanose, gentiobiose, rutinose, kojibiose, nigerose, robinose, neohesperidose, sucralose, and maltitol.Type: ApplicationFiled: October 2, 2014Publication date: July 21, 2016Applicant: NITTO DENKO CORPORATIONInventors: Eiji KIYOTOH, Mitsuhiko HORI, Daisuke ASARI, Arimichi OKAZAKI, Masahiro FUKASAKA